Fulgent Genetics Inc (FLGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fulgent Genetics Inc (FLGT) has a cash flow conversion efficiency ratio of -0.024x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.76 Million) by net assets ($995.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FLGT market cap for the company's overall valuation and market capitalisation.
Fulgent Genetics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Fulgent Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fulgent Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulgent Genetics Inc ranked by their cash flow conversion efficiency. Explore FLGT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DongHua Testing Technology Co Ltd
SHE:300354
|
0.043x |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
0.100x |
|
AGI Greenpac Limited
NSE:AGI
|
-0.035x |
|
Zhejiang Sf Oilless Bearing Co Ltd
SHE:300817
|
0.053x |
|
STINGRAY GROUP INC.
F:317A
|
N/A |
|
REGAL PARTNERS LTD.
F:OC7
|
N/A |
|
Tianshui Zhongxing Bio-technology Co Ltd
SHE:002772
|
0.058x |
|
PAR Technology Corporation
NYSE:PAR
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Fulgent Genetics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Fulgent Genetics Inc from 2014 to 2025. View Fulgent Genetics Inc (FLGT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.11 Billion | $-101.64 Million | -0.092x | -592.40% |
| 2024-12-31 | $1.13 Billion | $21.06 Million | 0.019x | -21.72% |
| 2023-12-31 | $1.13 Billion | $27.00 Million | 0.024x | -88.07% |
| 2022-12-31 | $1.27 Billion | $253.52 Million | 0.200x | -56.78% |
| 2021-12-31 | $1.17 Billion | $538.58 Million | 0.462x | +87.04% |
| 2020-12-31 | $569.39 Million | $140.63 Million | 0.247x | +270.57% |
| 2019-12-31 | $82.78 Million | $5.52 Million | 0.067x | +616.11% |
| 2018-12-31 | $52.27 Million | $-675.00K | -0.013x | -152.42% |
| 2017-12-31 | $54.03 Million | $1.33 Million | 0.025x | -69.53% |
| 2016-12-31 | $54.48 Million | $4.41 Million | 0.081x | +142.94% |
| 2015-12-31 | $5.15 Million | $-969.00K | -0.188x | +92.79% |
| 2014-12-31 | $1.68 Million | $-4.40 Million | -2.611x | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more